Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,28,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,26.5,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 37 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days),69380,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,24,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,33,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to38 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69382,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,16,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,33.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69385,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,16,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,33.9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69388,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,18,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,16.7,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69391,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,18.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69395,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,19,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,days,,15.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69398,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,11,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,17.4,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69407,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,10,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,14.1,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69410,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,7,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,16.3,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69413,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002386,DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini,female,0 days,14,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,11.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69416,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,21,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,18.7,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69418,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002387,DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini,female,0 days,19,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,17.3,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69420,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,female,0 days,21,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,16.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69422,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,17,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,25.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69424,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,32.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69427,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002386,DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini,female,0 days,18,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,31.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69429,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002387,DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini,female,0 days,9,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,28.4,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69431,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,female,0 days,14,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,28.9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69433,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,6,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,28.3,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69436,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,28,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,64,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 37 days,subcutaneous injection,37,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days),69378,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,24,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to38 days,subcutaneous injection,37,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69379,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,16,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69384,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,16,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,38,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69387,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,18,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,94,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38 days,subcutaneous injection,38,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69390,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,90,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,31,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69394,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,19,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,31,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69397,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,11,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,91,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38days,subcutaneous injection,38,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69406,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69409,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,7,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69412,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002386,DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini,female,0 days,14,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,86,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69415,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69426,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,6,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69435,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,28,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,10.7,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 37 days,subcutaneous injection,37,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days),69381,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,24,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,5.5,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to38 days,subcutaneous injection,37,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69383,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,16,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,6.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69386,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,16,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,4.9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69389,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,18,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,14.3,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31 days,subcutaneous injection,31,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69392,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,18,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,20.9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38 days,subcutaneous injection,38,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69393,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,22.6,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,31,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69396,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,19,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,11.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,31,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69399,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,11,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,17.6,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38days,subcutaneous injection,38,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69408,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,10,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,23.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69411,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,7,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,22.4,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69414,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002386,DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini,female,0 days,14,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,18.4,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69417,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,21,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,11.5,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,28,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69419,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002387,DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini,female,0 days,19,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,11.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,28,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69421,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,female,0 days,21,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,13.3,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,28,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69423,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,17,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69425,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,2.7,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69428,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002386,DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini,female,0 days,18,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,6,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69430,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002387,DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini,female,0 days,9,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,5.9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69432,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,female,0 days,14,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,7.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69434,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,6,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,7.5,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69437,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days)